Desensitization 12-step Calculator (Beta)
|
«
(Back)
|
Patient Name (optional):
|
Enter Drug Name:
|
Target (final - maintenance) dose:
mg
Standard Volume: mL
(Usually 100-250 ml)
|
|
Background Info / References
|
1] Castells
MC, Solensky R. Rapid drug desensitization for immediate
hypersensitivity reactions. UpToDate®. 2014;07. https://www.uptodate.com.
Accessed: 8/7/2014.
Desensitization key points:
-
Requirements before proceeding:
[1] Patient should have a proven history of an
immediate-type drug allergy AND [2] There
are NO acceptable
alternate drugs.
Immediate reactions - Occur within one hour of exposure. [Reactions include: flushing ,pruritus, urticaria,
shortness of breath, chest tightness, angioedema, N&V, hypotension,
etc. Delayed-reactions occur > 1 hour after
exposure.
-
Contraindications to desensitization:
Never attempt desensitization in patients with extreme
allergic responses such as Stevens-Johnson syndrome, toxic
epidermal necrolysis, erythema multiform or similar
reactions that include a desquamation or skin blistering
component. Also avoid desensitization in patients with a
history of the following types of reactions: hepatitis,
nephritis, serum sickness reactions.
- Ideally only highly trained specialists with experience
with desensitization procedures should perform the
technique.
- Patient's with a history of more severe reactions other
than those mentioned above may require a lengthy
desensitization procedure that is initiated with a much
lower concentration that is used by this program.
[Sixteen-step procedure exists].
- It is possible that late-occurring reactions may occur
after desensitization with prolonged therapy with the
offending agent such as serum sickness, hemolytic anemia,
and nephritis.
- REMEMBER that a desensitization procedure brings about
a TEMPORARY tolerance. Interruptions in therapy or
after discontinuation of therapy, the patient's
hypersensitivity may return QUICKLY.
- Most routes can be used for a desensitization procedure
including IV, oral, and subcutaneous. The final route
of administration can deviate from the initial route used
for desensitization. Example: IV desensitization procedure
--> oral therapy thereafter.
- The desensitization procedure may have to be aborted
for severe reactions including intractable hypotension or
laryngeal edema that does not immediately respond to
therapy with epinephrine. As mentioned earlier
experience with the desensitization process is imperative.
A 12-step algorithm has been used successfully at several
institutions for a variety of drugs in patients with immediate
hypersensitivity. This protocol uses three solutions
(100-250ml each). Solution 3: standard
therapeutic solution of the drug that is usually given IV.
Solution 2 is a 10-fold dilution of 3 and solution
1 is a 100-fold dilution of 2.
Desensitization has been performed with this protocol to
treat patients with an immediate hypersensitivity to the
following drugs: Penicillins and other beta-lactams, including ertapenem, imipenem, and
meropenem. Cephalosporins. Fluoroquinolones. Vancomycin.
Procedure length (average): 6 hours.
Sample copy of the algorithm using a
final dose of 1000mg and volume of 100ml. Note: the first
eleven steps are infused over 15 minutes at various infusion
rates (dose escalation).
For specialized instructions regarding management of symptoms
during this process as well as other important considerations,
please refer to the original source above.
|
2]
Sancho MC, Breslow R, Sloane D, Castells M.
Desensitization for Hypersensitivity Reactions to Medications.
French LE (ed): Adverse Cutaneous Drug Eruptions. Chem Immunol Allergy.
Basel, Karger, 2012, vol 97, pp 217-233.
Rapid drug desensitization (RDD):
-
Technique that induces temporary tolerance to a drug.
- Patients with IgE and non- IgE hypersensitivity
reactions (HSRs) can generally safely receive the offending
drug while inhibiting the targeted adverse reactions.
- Successful desensitization using the 12 step protocol
has been achieved with the following drugs: nafcillin, penicillin,
cefazolin, and ceftriaxone. Other agents were listed including
ceftazidime.
"Patients with negative skin testing should not require
desensitization."
|
3]
Castells M. Rapid desensitization for hypersensitivity reactions to
medications. Immunol Allergy Clin North Am 2009; 29:585.
Rapid Desensitization to B-Lactam antibiotics Including Penicillin and Cephalosporins Antibiotic and Number of Desensitization's
performed (2005-2006) - Brigham and Women’s Hospital -
using the 12-step protocol:
-------------------------------------
Ancef 1
Ceftaxidime 7
Ceftriaxone 4
Cefazolin 1
Ciprofloxacin 1
Ertapenem 1
Imipenem 9
Meropenem 1
Nafcillin 3
Penicillin 7
Piperacillin 3
Trimethoprim 1
Zosyn 3
----------------------------------- TOTAL 42 |
|
Sample of the program's output:
Solution: |
Total Volume |
Concentration |
Dose |
Solution 1 |
100 mL |
0.100 mg/mL |
10 mg |
Solution 2 |
100 mL |
1.00 mg/mL |
100 mg |
Solution 3 |
100 mL |
10.00 mg/mL |
1000 mg |
Step |
Solution# |
Rate (mL/hr) |
Time (minutes) |
Volume infused per step (mL) |
Dose administered with this
step (mg) |
Cumulative Dose (mg) |
1 |
1 |
2 |
15 |
0.5 |
0.050 |
0.050 |
2 |
1 |
5 |
15 |
1.25 |
0.125 |
0.175 |
3 |
1 |
10 |
15 |
2.5 |
0.25 |
0.425 |
4 |
1 |
20 |
15 |
5 |
0.5 |
0.925 |
5 |
2 |
5 |
15 |
1.25 |
1.25 |
2.175 |
6 |
2 |
10 |
15 |
2.5 |
2.5 |
4.675 |
7 |
2 |
20 |
15 |
5 |
5 |
9.675 |
8 |
2 |
40 |
15 |
10 |
10 |
19.675 |
9 |
3 |
10 |
15 |
2.5 |
25 |
44.675 |
10 |
3 |
20 |
15 |
5 |
50 |
94.675 |
11 |
3 |
40 |
15 |
10 |
100 |
194.675 |
12 |
3 |
80 |
60.40 |
80.53 |
805.325 |
1000 |
|
References
|
- Castells
MC, Solensky R. Rapid drug desensitization for immediate
hypersensitivity reactions. UpToDate®. 2014;07. https://www.uptodate.com.
Accessed: 8/7/2014.
- Castells M. Rapid desensitization for hypersensitivity reactions to
medications. Immunol Allergy Clin North Am 2009; 29:585.
- Sancho MC, Breslow R, Sloane D, Castells M. Desensitization for
Hypersensitivity Reactions to Medications. French LE (ed): Adverse
Cutaneous Drug Eruptions. Chem Immunol Allergy. Basel, Karger, 2012, vol
97, pp 217-233.
|